A subcutaneous (SC) immune anticancer drug that can be administered in 1–2 minutes by injection into the skin has been newly ...

Investors have bet new drugs can topple Merck’s Keytruda, but the evidence so far points to something smaller.

Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside pembrolizumab after surgery saw ...

A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...

Maintenance pembrolizumab plus olaparib yielded an ORR of 28% versus 18% with olaparib alone, indicating incremental antitumor activity in a biomarker-defined metastatic pancreatic cancer subgroup.

Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...

A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer ...

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  The pharmaceutical giant also narrowed its 2026 sales ...

After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC, Mizuho ...

After ICIJ’s The Cancer Calculus investigation exposed a market for falsified Keytruda, two sources confirmed Friday that ...

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...